Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 2, 2026

Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases
04:25

Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases

Published on: November 8, 2024

2.3K

Malignant hyperthermia.

Philip M Hopkins1, Pawan K Gupta2, Jonathan G Bilmen2

  • 1Leeds Institute of Biomedical & Clinical Sciences, University of Leeds, Leeds, United Kingdom; Malignant Hyperthermia Investigation Unit, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.

Handbook of Clinical Neurology
|November 22, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genotype-phenotype relationships in butyrylcholinesterase deficiency: a systematic review.

British journal of anaesthesia·2026
Same author

[<sup>68</sup>Ga]Ga-FAPI-46 PET/CT in Adrenocortical Neoplasm, Oncocytic Type.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Diagnostic certainty after investigation of perioperative hypersensitivity: a retrospective cohort analysis.

British journal of anaesthesia·2026
Same author

European Malignant Hyperthermia Group 2025 guidelines for the investigation of malignant hyperthermia susceptibility.

British journal of anaesthesia·2026
Same author

Beyond the Prostate: Incidental Detection of Male Breast Carcinoma on [<sup>18</sup>F]DCFPyl.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same author

Penicillin allergy risk stratification tool for use by non-allergists in the peri-operative setting: an agreement study and qualitative process evaluation.

Anaesthesia·2025
Same journal

Preface.

Handbook of clinical neurology·2026
Same journal

Foreword.

Handbook of clinical neurology·2026
Same journal

Fundus autofluorescence imaging.

Handbook of clinical neurology·2026
Same journal

The electroretinogram as a means to study the physiology of the retina.

Handbook of clinical neurology·2026
Same journal

Adaptive optics scanning light ophthalmoscopy.

Handbook of clinical neurology·2026
Same journal

Modeling the human retina in a dish: Advances and future directions.

Handbook of clinical neurology·2026
See all related articles

Malignant hyperthermia (MH) is a severe reaction during anesthesia, triggered by specific drugs in susceptible individuals. Prompt management is crucial as untreated MH is fatal.

Area of Science:

  • Anesthesiology
  • Genetics
  • Physiology

Background:

  • Malignant hyperthermia (MH) is a distinct heat illness occurring during general anesthesia.
  • Differential diagnosis of MH is complicated by the inability to assess mental status under anesthesia.
  • MH affects genetically predisposed individuals exposed to specific anesthetic agents.

Purpose of the Study:

  • To summarize the clinical features and management of Malignant hyperthermia.
  • To review the current understanding of the pathophysiology of MH.
  • To discuss the molecular genetics underlying MH.

Main Methods:

  • Review of clinical features and management strategies for MH.
  • Analysis of current research on the pathophysiology of MH.
Keywords:
Malignant hyperthermiaexcitation-contraction couplinggeneticsryanodine receptor calcium release channelskeletal muscle

More Related Videos

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

7.5K
In Vitro and In Vivo Delivery of Magnetic Nanoparticle Hyperthermia Using a Custom-Built Delivery System
06:45

In Vitro and In Vivo Delivery of Magnetic Nanoparticle Hyperthermia Using a Custom-Built Delivery System

Published on: July 2, 2020

4.8K

Related Experiment Videos

Last Updated: Feb 2, 2026

Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases
04:25

Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases

Published on: November 8, 2024

2.3K
Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

7.5K
In Vitro and In Vivo Delivery of Magnetic Nanoparticle Hyperthermia Using a Custom-Built Delivery System
06:45

In Vitro and In Vivo Delivery of Magnetic Nanoparticle Hyperthermia Using a Custom-Built Delivery System

Published on: July 2, 2020

4.8K
  • Examination of genetic defects associated with MH.

    • Main Results:

    • MH results from genetic defects affecting skeletal muscle excitation-contraction coupling and calcium regulation.
    • The RYR1 gene is most commonly implicated in MH.
    • Consequences include hypermetabolism, sustained muscle contraction, and potential for fatal outcomes if untreated.

    Conclusions:

    • MH is a life-threatening condition requiring prompt recognition and management.
    • Understanding the genetic basis and pathophysiology is key to improving patient outcomes.
    • Further research into RYR1 and other genetic factors is essential.